Acumen pharmaceuticals reports financial results for full year ended december 31, 2022 and business highlights

Charlottesville, va. and carmel, ind., march 27, 2023 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos), a clinical-stage biopharmaceutical company focused on developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (aΒos) and is designed for the treatment of alzheimer's disease (ad), today reported financial results for the full year ended december 31, 2022 and provided a business update.
ABOS Ratings Summary
ABOS Quant Ranking